EP3625212A4 - Agents psychotropes et leurs utilisations - Google Patents

Agents psychotropes et leurs utilisations Download PDF

Info

Publication number
EP3625212A4
EP3625212A4 EP18801735.4A EP18801735A EP3625212A4 EP 3625212 A4 EP3625212 A4 EP 3625212A4 EP 18801735 A EP18801735 A EP 18801735A EP 3625212 A4 EP3625212 A4 EP 3625212A4
Authority
EP
European Patent Office
Prior art keywords
psychotropic agents
psychotropic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18801735.4A
Other languages
German (de)
English (en)
Other versions
EP3625212A2 (fr
Inventor
Andrew R. VAINO
Vincent T. GRATTAN
Zachary PRENSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LB Pharmaceuticals Inc
Original Assignee
LB Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LB Pharmaceuticals Inc filed Critical LB Pharmaceuticals Inc
Publication of EP3625212A2 publication Critical patent/EP3625212A2/fr
Publication of EP3625212A4 publication Critical patent/EP3625212A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18801735.4A 2017-05-18 2018-05-18 Agents psychotropes et leurs utilisations Pending EP3625212A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508263P 2017-05-18 2017-05-18
PCT/US2018/033552 WO2018213813A2 (fr) 2017-05-18 2018-05-18 Agents psychotropes et leurs utilisations

Publications (2)

Publication Number Publication Date
EP3625212A2 EP3625212A2 (fr) 2020-03-25
EP3625212A4 true EP3625212A4 (fr) 2021-03-31

Family

ID=64274762

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18801735.4A Pending EP3625212A4 (fr) 2017-05-18 2018-05-18 Agents psychotropes et leurs utilisations

Country Status (3)

Country Link
EP (1) EP3625212A4 (fr)
CN (1) CN110944630A (fr)
WO (1) WO2018213813A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377421B2 (en) 2016-11-28 2022-07-05 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
BR112019010127A2 (pt) 2016-11-28 2019-08-20 Lb Pharmaceuticals Inc agentes psicotrópicos e usos dos mesmos
CN117074579B (zh) * 2023-10-16 2023-12-22 江苏东科康德药业有限公司 一种氨磺必利口服溶液有关物质的分析方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019113079A1 (fr) * 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Mélanges non racémiques et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210660A (en) * 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
FR2753376B1 (fr) * 1996-09-18 1998-10-16 Synthelabo Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20100105755A1 (en) * 2008-09-12 2010-04-29 Auspex Pharmaceuticals, Inc. Substituted benzamide modulators of dopamine receptor
BR112019010127A2 (pt) * 2016-11-28 2019-08-20 Lb Pharmaceuticals Inc agentes psicotrópicos e usos dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019113079A1 (fr) * 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Mélanges non racémiques et leurs utilisations

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ASCALONE V ET AL: "Stereospecific determination of amisulpride, a new benzamide derivative, in human plasma and urine by automated solid-phase extraction and liquid chromatography on a chiral column Application to pharmacokinetics", JOURNAL OF CHROMATOGRAPHY B, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 676, no. 1, 9 February 1996 (1996-02-09), pages 95 - 105, XP004044223, ISSN: 0378-4347, DOI: 10.1016/0378-4347(95)00418-1 *
ATHEIR I ABBAS ET AL: "Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo", PSYCHOPHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 205, no. 1, 1 April 2009 (2009-04-01), pages 119 - 128, XP019702397, ISSN: 1432-2072 *
DONAHUE TIMOTHY J ET AL: "Discriminative stimulus properties of the atypical antipsychotic amisulpride: comparison to its isomers and to other benzamide derivatives, antipsychotic, antidepressant, and antianxiety drugs in C57BL/6 mice", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 234, no. 23, 18 September 2017 (2017-09-18), pages 3507 - 3520, XP036365403, ISSN: 0033-3158, [retrieved on 20170918], DOI: 10.1007/S00213-017-4738-Y *
GRATTAN VINCENT ET AL: "Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D 2 and D 3 , while R Enantiomers Engage 5-HT 7", ACS OMEGA, vol. 4, no. 9, 15 August 2019 (2019-08-15), US, pages 14151 - 14154, XP055776545, ISSN: 2470-1343, Retrieved from the Internet <URL:http://pubs.acs.org/doi/pdf/10.1021/acsomega.9b02144> DOI: 10.1021/acsomega.9b02144 *
IWANAMI S ET AL: "SYNTHESIS AND NEUROLEPTIC ACTIVITY OF BENZAMIDES. ÖCIS-N-(1-BENZYL-2-METHYLPYRROLIDIN-3-YL)-5-CHLORO-2-METHOXY-4- (METHYLAMINO)BENZAMIDE AND RELATED COMPOUNDS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 24, no. 10, 1 October 1981 (1981-10-01), pages 1224 - 1230, XP000611487, ISSN: 0022-2623, DOI: 10.1021/JM00142A019 *
MARCHESE GIORGIO ET AL: "Effect of the amisulpride isomers on rat catalepsy", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 444, no. 1-2, 1 May 2002 (2002-05-01), NL, pages 69 - 74, XP055776556, ISSN: 0014-2999, DOI: 10.1016/S0014-2999(02)01602-3 *
ROSENZWEIG P ET AL: "A REVIEW OF THE PHARMACOKINETICS, TOLERABILITY AND PHARMACODYNAMICS OF AMISULPRIDE IN HEALTHY VOLUNTEERS", HUMAN PSYCHOPHARMACOLOGY. CLINICAL AND EXPERIMENTAL, JOHN WILEY & SONS LTD, XX, vol. 17, no. 1, 1 January 2002 (2002-01-01), pages 1 - 13, XP009034808, ISSN: 0885-6222, DOI: 10.1002/HUP.320 *

Also Published As

Publication number Publication date
WO2018213813A2 (fr) 2018-11-22
WO2018213813A8 (fr) 2019-11-07
WO2018213813A3 (fr) 2019-12-12
CN110944630A (zh) 2020-03-31
EP3625212A2 (fr) 2020-03-25

Similar Documents

Publication Publication Date Title
EP3694861A4 (fr) Composés hétérocycliques et leurs utilisations
EP3681888A4 (fr) Composés de pyrazolopyrimidinone et leurs utilisations
EP3529279A4 (fr) Agents de liaison à cd133 et leurs utilisations
EP3303379A4 (fr) Agents de liaison à tigit et leurs utilisations
EP3253890A4 (fr) Agents de liaison à la tnfrsf et leurs utilisations
EP3720502A4 (fr) Produits cytobiologiques et leurs utilisations thérapeutiques
EP3694509A4 (fr) Composés hétérocycliques et leurs utilisations
EP3511407A4 (fr) Christensenella intestinihominis et son application
EP3676247B8 (fr) Dérivés d&#39;aztréonam et utilisations associées
EP3700934A4 (fr) Composés et utilisations de ces composés
EP3544606A4 (fr) Agents psychotropes et leurs utilisations
EP3560517A4 (fr) Conjugué de médicament aptamère et son utilisation
EP3526215A4 (fr) Dérivés de n-acyléthanolamide et leurs utilisations
EP3686204A4 (fr) Dérivés de thiénodiazépine et leur application
EP3585814A4 (fr) Agents de liaison à l&#39;egfr et leurs utilisations
EP3569202A4 (fr) Outil de pressage du sacrum et unité de pressage du sacrum
SG11202008543RA (en) Pyrrolidineamide derivatives and uses thereof
EP3691629A4 (fr) Formulations nutriment-spores et leurs utilisations
EP3565531A4 (fr) Nanovaccins à base de nicotine et leurs utilisations
EP3681540A4 (fr) Agents à base de chlorotoxine et leurs utilisations
EP3683303A4 (fr) Megamonas funiformis et ses applications
EP3625212A4 (fr) Agents psychotropes et leurs utilisations
EP3721853A4 (fr) Sac muni d&#39;un orifice et sac muni d&#39;un capuchon
GB202004930D0 (en) Composition and uses thereof
EP3573611A4 (fr) Composés amide et leur utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191120

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40026052

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0207090000

Ipc: A61K0031400000

A4 Supplementary search report drawn up and despatched

Effective date: 20210301

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/24 20060101ALI20210223BHEP

Ipc: A61K 45/06 20060101ALI20210223BHEP

Ipc: A61K 31/166 20060101ALI20210223BHEP

Ipc: C07D 207/09 20060101ALI20210223BHEP

Ipc: A61P 25/18 20060101ALI20210223BHEP

Ipc: A61K 31/40 20060101AFI20210223BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230330